Surrogate end points in heart failure trials

Am Heart J. 2003 Feb;145(2 Suppl):S67-70. doi: 10.1067/mhj.2003.159.
No abstract available

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Anti-Arrhythmia Agents / adverse effects
  • Arrhythmias, Cardiac / drug therapy
  • Arrhythmias, Cardiac / mortality
  • Biomarkers / blood
  • Disease Progression
  • Exercise Tolerance / drug effects
  • Exercise Tolerance / physiology
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Heart Failure / mortality*
  • Heart Failure / physiopathology
  • Humans
  • Neurotransmitter Agents / antagonists & inhibitors*
  • Neurotransmitter Agents / blood
  • Norepinephrine / blood
  • Stroke Volume / drug effects
  • Stroke Volume / physiology
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use
  • Ventricular Function, Left / drug effects*
  • Ventricular Function, Left / physiology
  • Ventricular Remodeling / drug effects
  • Ventricular Remodeling / physiology

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Biomarkers
  • Neurotransmitter Agents
  • Vasodilator Agents
  • Norepinephrine